A Versatile Biomimic Nanotemplating Fluidic Assay for Multiplex Quantitative Monitoring of Viral Respiratory Infections and Immune Responses in Saliva and Blood. Issue 33 (17th October 2022)

• Record Type: Journal Article
• Authors: Siavash Moakhar, Roozbeh; del Real Mata, Carolina; Jalali, Mahsa; Shafique, Houda; Sanati, Alireza; de Vries, Justin; Strauss, Julia; AbdElFatah, Tamer; Ghasemi, Fahimeh; McLean, Myles; I. Hosseini, Imman; Lu, Yao; Yedire, Sripadh Guptha; Mahshid, Sahar Sadat; Tabatabaiefar, Mohammad Amin; Liang, Chen; Mahshid, Sara
• Is Part Of: Advanced science. Volume 9:Issue 33(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-10-17
• Subjects: impedimetric biosensors -- microfluidic devices -- molecularly imprinted polymers -- multiplexed testing -- viral respiratory infection; Science -- Periodicals; 505
• DOI: 10.1002/advs.202204246
• Languages: English
• ISSNs: 2198-3844

Abstract

Abstract: The last pandemic exposed critical gaps in monitoring and mitigating the spread of viral respiratory infections at the point‐of‐need. A cost‐effective multiplexed fluidic device (NFluidEX), as a home‐test kit analogous to a glucometer, that uses saliva and blood for parallel quantitative detection of viral infection and body's immune response in an automated manner within 11 min is proposed. The technology integrates a versatile biomimetic receptor based on molecularly imprinted polymers in a core–shell structure with nano gold electrodes, a multiplexed fluidic‐impedimetric readout, built‐in saliva collection/preparation, and smartphone‐enabled data acquisition and interpretation. NFluidEX is validated with Influenza A H1N1 and SARS‐CoV‐2 (original strain and variants of concern), and achieves low detection limit in saliva and blood for the viral proteins and the anti‐receptor binding domain (RBD) Immunoglobulin G (IgG) and Immunoglobulin M (IgM), respectively. It is demonstrated that nanoprotrusions of gold electrodes are essential for the fine templating of antibodies and spike proteins during molecular imprinting, and differentiation of IgG and IgM in whole blood. In the clinical setting, NFluidEX achieves 100% sensitivity and 100% specificity by testing 44 COVID‐positive and 25 COVID‐negative saliva and blood samples on par with the real‐time quantitative polymerase chain reaction ( p < 0.001, 95% confidence) and the enzyme‐linked immunosorbent assay. Abstract : The authors present a nanostructured microfluidic electrochemical multiplexed device (NFluidEX) for parallel quantitative detection of viral proteins and antibodies in untreated saliva and whole blood within 11 minutes. This point‐of‐care platform is clinically and quantitatively validated with viral respiratory viruses to yield 100% sensitivity and 100% specificity against gold standard methods.